Top Research Reports For Costco, Exxon & Bristol-Myers
Zacks Investment Research | Oct 06, 2016 01:26AM ET
Thursday, October 6, 2016
Today's Research Daily features new research reports on 16 major stocks, including Costco (NASDAQ:COST), ExxonMobil (NYSE:XOM) and Bristol-Myers (BMY).
Costco shares have been laggards lately as earnings performance has been weighed down by stiff competition and cautious consumer spending trends. However, the analyst emphasizes that Costco continues to be one of the dominant retail wholesalers based on its breadth and quality of merchandise offered. Also, the company’s diversification strategy acts as a natural hedge against risks that may arise in specific markets. (You can )
ExxonMobil shares have outperformed the broader market this year on the back oil's positive momentum, though the stock has lagged oil-ier super majors like Chevron (NYSE:CVX) and the major E&P's. This reflects the oil giant's balanced business mix that make it a relatively defensive oil play; the stock doesn't rise as much as its peers in a rising oil price environment, but it doesn't fall by that much when the commodity is heading south either. With a stable cash position, Exxon Mobil’s balance sheet is one of the best in the industry. Exxon's safe and stable dividend (currently yielding an attractive 3.5%) is another key positive. (You can )
Bristol-Myers shares have been depressed for some time now and are down 20% year-to-date. The company raised its guidance for 2016 earnings once again, buoyed by strong trends across the business, primarily Opdivo and Eliquis. The analyst likes Bristol-Myers’ efforts to develop its pipeline. It has been working on strengthening its product portfolio as well as its pipeline through acquisitions and deals. Also, Bristol-Myers is working on expanding the label of approved drugs including Opdivo, Orencia and Yervoy. (You can )
Other noteworthy reports we are featuring today include Shire (SHPG), Baxter (BAX) and Darden (DRI).
Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
You can find all of today's stock research reports >>
Sheraz Mian
Director of Research
Note: If you want an email notification each time Sheraz publishes a new article, please >>>
Today's Must Read/h6
Featured Reports/h6
The Zacks analyst thinks Weyerhaeuser's deal to sell-off its printing papers business will enable the company to focus on its core timber, land, and forest products business.
The Zacks analyst believes that efforts to drive demand and higher revenues aided Carnival to beat on Q3 earnings. The company also upped its earnings outlook on the back of strong booking trends.
The covering analyst thinks Washington Federal's additional share buyback authorization will enhance shareholder value. However, escalated expenses remain a headwind.
The Zacks analyst thinks State Street is also set to capitalize on growth opportunities based on its sturdy capital position.
The covering analyst thinks that Shire's rare disease portfolio coupled with recent acquisitions should propel the company's growth prospects further. However, generic competition remains a concern.
The covering analyst likes Marathon Petroleum for its scale advantage, impressive asset quality and extensive midstream/retail network.
The Zacks analyst think Baxter will gain from new launches like intravenous nutrition product NUMETA G13E. Lower cyclophosphamide sales will hurt the Integrated Pharmacy Solutions franchise business
The Zacks analyst thinks Weyerhaeuser's deal to sell-off its printing papers business will enable the company to focus on its core timber, land, and forest products business.
The Zacks analyst believes that efforts to drive demand and higher revenues aided Carnival to beat on Q3 earnings. The company also upped its earnings outlook on the back of strong booking trends.
The covering analyst thinks Washington Federal's additional share buyback authorization will enhance shareholder value. However, escalated expenses remain a headwind.
The Zacks analyst thinks State Street is also set to capitalize on growth opportunities based on its sturdy capital position.
The covering analyst thinks that Shire's rare disease portfolio coupled with recent acquisitions should propel the company's growth prospects further. However, generic competition remains a concern.
The covering analyst likes Marathon Petroleum for its scale advantage, impressive asset quality and extensive midstream/retail network.
The Zacks analyst think Baxter will gain from new launches like intravenous nutrition product NUMETA G13E. Lower cyclophosphamide sales will hurt the Integrated Pharmacy Solutions franchise business
New Upgrades/h6
The Zacks analyst remains upbeat on Darden post its Q1 earnings performance. Sales initiatives like menu innovation, technology-driven moves along with efforts to curtail costs should drive growth.
The Zacks analyst thinks increasing demand for media services, speedy growth of technologies, massive proliferation of channels and strategic acquisitions will improve the Omnicom's top line
According to the covering analyst, CarMax's focus on the used-vehicle market, aggressive store-expansion and share repurchases should help it outperform peers.
The Zacks analyst remains upbeat on Darden post its Q1 earnings performance. Sales initiatives like menu innovation, technology-driven moves along with efforts to curtail costs should drive growth.
The Zacks analyst thinks increasing demand for media services, speedy growth of technologies, massive proliferation of channels and strategic acquisitions will improve the Omnicom's top line
According to the covering analyst, CarMax's focus on the used-vehicle market, aggressive store-expansion and share repurchases should help it outperform peers.
New Downgrades/h6
According to the Zacks analyst, weak end markets and FX headwinds will continue to offset gains from ABB's "Next Level Strategy", lucrative partnership deals & infrastructure market stronghold.
The covering analyst believes that rising expenses, intense competition due to increased market consolidation and stringent regulations are some of the headwinds faced by the company.
The Zacks analyst believes that though Analog Devices' strength in the industrial, auto and communication markets is a positive, it is largely offset by significant weakness in the consumer business.
According to the Zacks analyst, weak end markets and FX headwinds will continue to offset gains from ABB's "Next Level Strategy", lucrative partnership deals & infrastructure market stronghold.
The covering analyst believes that rising expenses, intense competition due to increased market consolidation and stringent regulations are some of the headwinds faced by the company.
The Zacks analyst believes that though Analog Devices' strength in the industrial, auto and communication markets is a positive, it is largely offset by significant weakness in the consumer business.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.